share_log

君实生物(688180.SH):JS125获得药物临床试验申请受理通知书

Junshi Bio (688180.SH): JS125 has received a letter of clinical trial application acceptance notice for drugs.

Gelonghui Finance ·  Jul 9 07:32

Gelonghui July 9 丨 Junshi Biotech (688180.SH) announced that the company received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the clinical trial application for WJ47156 tablets (project code “JS125”) was accepted. JS125 is a target histone deacetylase (“HDACs”) inhibitor. It was developed by the company in cooperation with Weijing Biomedical Technology (Shanghai) Co., Ltd., and is intended for the treatment of malignant tumors. It is an epigenetic regulator drug.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment